secwatch / observer
8-K filed October 23, 2023, 7:59 PM ET ticker MDT CIK 0001613103
other material confidence high sentiment neutral materiality 0.50

Medtronic shareholders approve 2024 ESPP (30M shares); directors re-elected with notable dissent

Medtronic plc

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Medtronic plc shareholders approved Authorize overseas market purchases of ordinary shares at the 2023-10-19 meeting.

Outcome
passed
Meeting
2023-10-19
Exact text from the filing
7. The shareholders approved authorization of the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. FOR AGAINST ABSTAIN 1,107,883,517 52,096,146 4,187,303
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Medtronic plc shareholders approved Election of eleven directors to hold office until the 2024 Annual General Meeting at the 2023-10-19 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-10-19
Exact text from the filing
1. The shareholders elected each of the eleven nominees to the Board of Directors, to hold office until the 2024 Annual General Meeting of the Company and until his or her successor is elected, as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE Craig Arnold 1,015,233,892 25,512,208 864,144 122,556,722
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Medtronic plc shareholders approved Approve 2024 Employee Stock Purchase Plan at the 2023-10-19 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2023-10-19
Exact text from the filing
4. The shareholders approved the Company's 2024 Employee Stock Purchase Plan. FOR AGAINST ABSTAIN BROKER NON-VOTE 1,033,704,001 3,320,010 4,586,233 122,556,722
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Medtronic plc shareholders approved Renew Board's authority to issue shares at the 2023-10-19 meeting.

Outcome
passed
Meeting
2023-10-19
Exact text from the filing
5. The shareholders approved renewal of the Board’s authority to issue shares. FOR AGAINST ABSTAIN 1,145,356,737 16,259,098 2,551,131
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Medtronic plc shareholders approved Renew Board's authority to opt out of pre-emption rights at the 2023-10-19 meeting.

Outcome
passed
Meeting
2023-10-19
Exact text from the filing
6. The shareholders approved renewal of the Board’s authority to opt out of pre-emption rights. FOR AGAINST ABSTAIN 1,090,829,831 70,342,442 2,994,693
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Medtronic plc shareholders approved Ratify appointment of PricewaterhouseCoopers LLP as independent auditor and authorize Board to set remuneration at the 2023-10-19 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-10-19
Exact text from the filing
2. The shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2024 and authorized, in a binding vote, the Company’s Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration. FOR AGAINST ABSTAIN 1,060,656,333 101,691,327 1,819,306
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Medtronic plc shareholders approved Non-binding advisory vote on named executive officer compensation at the 2023-10-19 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-10-19
Exact text from the filing
3. The shareholders approved, on a non-binding advisory basis, the compensation awarded to the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 968,139,099 68,905,223 4,565,922 122,556,722
View on SEC.gov

560 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Medtronic plc filing history →

Source: SEC EDGAR
accession 0001613103-23-000132
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.